Sarcopenia Market
Key Highlights
- The Sarcopenia market is expected to strengthen as awareness of the disease increases and more effective interventions are being developed.
- It is expected that the number of Diagnosed Prevalent Cases of Sarcopenia will continue to increase due to population growth and several factors, including age, sedentary lifestyle, poor nutrition, chronic diseases, hormonal changes, and inflammation.
- The United States has a higher Sarcopenia prevalence than Japan, the EU4, and the UK. The disease is fast evolving into a significant public health issue with rising hospitalizations for sarcopenia- associated disabilities
- Biophytis, MyMD Pharmaceuticals, Biophytis, Dystrogen Therapeutics, Rejuvenate Biomed, Oncocross Therapeutics, OPKO health, NMD Pharma, Rubedo Life Sciences, Immunoforge, and others, currently have assets in early-mid stage development to treat Sarcopenia. The entry of these therapies is anticipated to considerably impact the market and fulfill the Sarcopenia unmet needs for curative treatment.
Request for unlocking the CAGR for Sarcopenia Market
Report Highlights
DelveInsight’s report titled “Sarcopenia – Market Insights, Epidemiology, and Market Forecast – 2032” comprehensively analyzes the Sarcopenia market, including market insights, market forecasts, drug uptakes, and drug penetration.
The report examines historical epidemiology data for Diagnosed Prevalent Cases and projects the same for the forecast period. Sarcopenia-diagnosed cases are further segmented by gender. The report also offers an in-depth understanding of various aspects of the disease, including diagnosis algorithm, prescription patterns, physician perceptions on treatment, and current and future market developments for the 7MM, including the United States, EU4 (Germany, France, Italy, and Spain) and the UK, and Japan from 2019 to 2032.
We provide country-wise in-depth analysis of the pipeline assets across different stages of development (Phase III and Phase II), emerging trends, and comparative analysis of the pipeline products supporting the clients in their decision-making process regarding their therapeutic portfolio.
To gauge the market’s overall potential and recognize business opportunities, the report discusses the existing Sarcopenia treatment practices and highlights Sarcopenia's unmet needs.
Sarcopenia Market Outlook
Early recognition and intervention is the key to improved outcomes in patients with Sarcopenia. Currently, no pharmaceutical agents have received FDA approval specifically for treating Sarcopenia. The current treatment landscape for Sarcopenia primarily involves non-pharmacological interventions such as nutritional supplementation, resistance training, exercise, and vibrational therapy. Comprehensive exercise-based treatment interventions that combine resistance training with nutritional intervention are considered effective in improving Sarcopenia and are often recommended over individual interventions.
Research and development activities in Sarcopenia aim to discover potential pharmacological therapies and novel treatment approaches. This involves the investigation of drug candidates that specifically target muscle mass and function. Examples of such candidates include selective androgen receptor modulators (SARMs), myostatin inhibitors, and other anabolic agents.
According to DelveInsight, the Sarcopenia market is expected to witness considerable changes in the 7MM during the study period 2019–2032.
Sarcopenia Market Segmentation
DelveInsight’s Sarcopenia Market report provides a detailed outlook of the current and future market of Sarcopenia, segmented by countries, by therapies, and by classes to emphasize the changing market dynamics over the forecast period.
Sarcopenia Market Size by Countries
The total market of Sarcopenia is analyzed for individual countries (the United States Market, EU4 (Germany, France, Italy, and Spain) and the UK market, and Japan). Due to many Diagnosed Prevalent Cases and the higher cost of therapies, the United States captured a higher share of the Sarcopenia market in 2022. It is expected to continue to dominate the Sarcopenia market, with plausible early entries of emerging products.
Country-wise Market Size Distribution of Sarcopenia
Sarcopenia Market Size by Therapies
The market size for therapies targeting Sarcopenia encompasses various approaches. This includes exercise and physical therapy interventions, nutritional supplements to support muscle health, ongoing developments in pharmacological interventions targeting muscle protein synthesis and hormone modulation, and potential combination therapies. The market size is subject to regional variations, emerging treatments, healthcare policies, reimbursement systems, and the level of awareness and diagnosis of Sarcopenia in the population. Sarcopenia cannot be diagnosed through a specific test or by assessing a specific level of muscle mass. Currently, there are no approved drugs or treatment therapies for Sarcopenia, despite intense competition among companies such as Biophytis, MyMD Pharmaceuticals, Biophytis, Dystrogen Therapeutics, Rejuvenate Biomed, Oncocross Therapeutics, OPKO Health, NMD Pharma, Rubedo Life Sciences, Immunoforge, and others striving to develop their molecules and bring them to the market. Newer technologies are being developed in the market that can play a major role in stimulating the growth of the Sarcopenia market.
Market Share Distribution of Sarcopenia by Therapies in 2032
Note: Detailed market segment assessment will be provided in the final report.
Drug Chapters
Sarcopenia Emerging Drugs
The therapeutic treatments currently available in the landscape of Sarcopenia aim to mitigate the complications associated with the condition. The dynamics of the Sarcopenia market are expected to change, primarily due to increased healthcare spending worldwide. Market players such as Biophytis, Rejuvenate Biomed, and others are actively involved in developing Sarcopenia treatments.
Sarconeos (BIO101): Biophytis
Biophytis’ lead drug candidate, Sarconeos (BIO101), is an orally administered small molecule in development for treating neuromuscular diseases. Sarconeos (BIO101) is about to progress in Phase III for Sarcopenia.
RJx-01: Rejuvenate Biomed
RJx-01 is a lead drug of Rejuvenate developed to treat acute and chronic Sarcopenia, a muscle disease defined by the loss of muscle strength, quality, and mass. A Phase Ib study is currently ongoing, in which its effect on disuse-induced Sarcopenia is being assessed. Rejuvenate is planning a subsequent Phase IIb trial to evaluate the effect of RJx-01 on patients with Sarcopenia. Thereafter, the company aims to out-license the drug candidate for Phase III.
Note: Detailed Sarcopenia emerging therapies assessment will be provided in the final report.
Sarcopenia Drugs Uptake
This section focuses on the sales uptake of potential Sarcopenia drugs anticipated to be launched in the Sarcopenia market between 2023 and 2032. It estimates the market penetration of the drugs for a given country, examining their impact within and across classes and segments. It also touches upon the financial and regulatory decisions contributing to the probability of success (PoS) of the drugs in the market.
Note: Detailed assessment of drug uptake and attribute analysis will be provided in the full report on Sarcopenia.
Sarcopenia Pipeline Development Activities
The Sarcopenia Pipeline report covers detailed information on collaborations, acquisition and merger, licensing, patent details, and other information for Sarcopenia emerging therapies.
Sarcopenia Epidemiology
This section provides a glimpse of the Sarcopenia epidemiology in the United States, EU4 (Germany, France, Italy, Spain), and the United Kingdom, and Japan.
The Sarcopenia epidemiology section provides insights into the historical, current, and forecasted trends of the Sarcopenia patient pool segmented by gender. This part of the report also provides the diagnosed and treated patient pools, their trends, and assumptions undertaken.
Key Findings
- DelveInsight estimates that Diagnosed Prevalent Cases of Sarcopenia across the 7MM were approximately 36 million in 2022.
- As per DelveInsight’s estimates, in 2022, the total Diagnosed Prevalent Cases for Sarcopenia were highest in the United States, accounting for approximately 53% of the total Diagnosed Prevalent Cases.
- Amongst the EU4 and the UK, Italy had the highest number of cases, followed by Germany, while Spain accounted for the least number of sarcopenia cases in 2022.
- In 2022, the most Diagnosed Prevalent Cases of Sarcopenia in the United States were found to be in males, accounting for 56% of the total cases. A similar trend was observed in the EU4 and the UK, where a higher percentage of cases were also reported in males.
- With the anticipation of a growing elderly population, DelveInsight foresees an increase in the diagnosed prevalent cases of Sarcopenia, considering the influence of advanced age on the development of diseases. Given the current diagnosed prevalent cases of this condition, projected population trends, and the absence of approved treatments, Sarcopenia presents a significant market potential.
Sarcopenia Market Access and Reimbursement
DelveInsight’s Sarcopenia Market report provides a descriptive overview of the market access and reimbursement scenario. This section includes a detailed analysis of the country-wise healthcare system for each therapy, illuminating the market access, reimbursement policies, and health technology assessments.
KOL Views
To keep up with current market trends and fulfill gaps in secondary findings, we conduct interviews with KOLs and SMEs’ working in the Sarcopenia domain. Their opinions understand and validate current and emerging therapy treatment patterns or Sarcopenia market trends. This will support the clients with potential upcoming novel treatments by identifying the overall scenario of the market and the Sarcopenia unmet needs.
Sarcopenia: KOL Insights
DelveInsight’s analysts connected with 50+ KOLs to gather insights; however, interviews were conducted with 15+ KOLs in the 7MM. These KOLs were from organizations, institutes, hospitals, etc., such as Servicio de Geriatría, Hospital Universitario Ramón y Cajal (IRYCIS), Madrid in Spain; Research Department, Centre Hospitalier Universitaire de Clermont-Ferrand, Clermont-Ferrand in France, and others.
“Sarcopenia impacts both males and females, although there are notable variations in its prevalence and progression between genders. Typically, Sarcopenia is more prevalent in males compared to females. However, postmenopausal women may experience a more accelerated decline in muscle mass and strength than their male counterparts.”
“About one to two third people in the age group of 80 and above are said to have Sarcopenia.”
Sarcopenia Diagnosis and Treatment Algorithm
The diagnosis of Sarcopenia typically involves a combination of Sarcopenia clinical trials assessment, physical performance tests, and imaging techniques. This can be done using various techniques such as dual-energy x-ray absorptiometry (DXA), bioelectrical impedance analysis (BIA), or computed tomography (CT) scans. Several organizations and expert groups have established diagnostic criteria and algorithms for Sarcopenia. For example, the European Working Group on Sarcopenia in Older People (EWGSOP) and the Asian Working Group for Sarcopenia (AWGS) have defined specific criteria involving muscle mass, muscle strength, and physical performance to diagnose Sarcopenia.
The treatment of Sarcopenia typically involves a multifaceted approach that includes resistance training to stimulate muscle growth and improve strength, nutritional interventions to ensure adequate protein intake, and vitamin D supplementation if deficiency is present.
Lack of approved pharmacological therapies, patient compliance, and recurrence of symptoms are major challenges associated with treating Sarcopenia. In advanced stages of Sarcopenia, muscle loss may become irreversible. This makes early detection and intervention crucial to prevent or slow down the progression of Sarcopenia and maximize treatment effectiveness. However, identifying Sarcopenia in its early stages can be challenging, as it may not present noticeable symptoms until substantial muscle loss has occurred.
Competitive Intelligence Analysis
We perform Competitive and Market Intelligence analysis of the Sarcopenia Market using various Competitive Intelligence tools, including SWOT analysis, Market entry strategies, etc. The inclusion of the analysis entirely depends upon the data availability.
Sarcopenia Report Insights
- Patient-Based Sarcopenia Market Forecasting
- Therapeutic Approaches
- Sarcopenia Pipeline Analysis
- Sarcopenia Market Size and Trends
- Market Opportunities
- Impact of Upcoming Therapies
Sarcopenia Report Key Strengths
- Sarcopenia 10 Years Market Forecast
- The 7MM Coverage
- Sarcopenia Epidemiology Segmentation
- Key Cross Competition
- Highly Analyzed Market
- Sarcopenia Drugs Uptake
Sarcopenia Report Assessment
- Sarcopenia Current Treatment Practices
- Sarcopenia Unmet Needs
- Sarcopenia Pipeline Product Profiles
- Sarcopenia Market Attractiveness
Key Questions
- What was the Sarcopenia drug class share (%) distribution in 2019, and how it would likely change in 2032?
- What would be the Sarcopenia total market size and market size by therapies across the 7MM during the forecast period (2023–2032)?
- What are the key findings of the market across the 7MM, and what country will have the largest Sarcopenia market size during the forecast period (2023–2032)?
- At what CAGR is the Sarcopenia market expected to grow by 7MM during the forecast period (2023–2032)?
- What factors drive the epidemiology trend for the 7MM covering the United States, the EU4 (Germany, Spain, France, Italy), the UK, and Japan?
- What are the Sarcopenia-marketed drugs and their respective MoA, regulatory milestones, product development activities, advantages, disadvantages, safety, efficacy, etc.?
- How many companies are developing therapies for the treatment of Sarcopenia?
- How many therapies are in development by each company for Sarcopenia treatment?
- How many are emerging therapies in the mid-stage and late stage of development for Sarcopenia treatment?
